Pricing Log in Create free account
Saturday 17 October 2026 Export LIVN’s income statement to Excel — free account

LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

LivaNova PLC (LIVN) Business Profile

Updated before January 2025

Company Overview

LivaNova PLC (NASDAQ: LIVN) is a global medical technology company that specializes in developing and delivering innovative therapeutic solutions. Headquartered in London, United Kingdom, LivaNova was established in 2015 following the merger of Sorin Group, an Italian medical device company, and Cyberonics, a U.S.-based leader in neuromodulation. This merger combined decades of expertise in cardiac surgery, neuromodulation, and other medical technologies, creating a diversified portfolio of life-enhancing products.

The company operates in over 100 countries and employs thousands of professionals worldwide. LivaNova’s leadership team is composed of seasoned executives with extensive experience in the healthcare and medical device industries. Damien McDonald serves as the Chief Executive Officer (CEO), bringing a strong background in global healthcare management. The company’s board of directors includes experts in finance, healthcare, and technology, ensuring a well-rounded strategic direction.

Core Business Segments

LivaNova operates through two primary business segments: Cardiovascular and Neuromodulation. These segments encompass a wide range of products and services designed to address critical medical needs.

1. Cardiovascular

LivaNova is a leader in the cardiovascular space, offering products that support cardiac surgery and other heart-related treatments. Key offerings include:

  • Heart-Lung Machines: Advanced systems used during open-heart surgeries to maintain circulation and oxygenation.
  • Oxygenators: Devices that provide oxygen to the blood during cardiac procedures.
  • Perceval Valve: A sutureless aortic heart valve designed for minimally invasive procedures.
  • Cannulae and Accessories: A range of products supporting extracorporeal circulation during surgeries.

2. Neuromodulation

The Neuromodulation segment focuses on innovative therapies for neurological and psychiatric conditions. Key products include:

  • Vagus Nerve Stimulation (VNS) Therapy: A treatment for drug-resistant epilepsy and depression.
  • SenTiva Generator: A next-generation VNS device offering personalized therapy for epilepsy patients.
  • Implantable Pulse Generators: Devices that deliver electrical stimulation to the vagus nerve.

Business Model

LivaNova’s business model revolves around the integration of cutting-edge medical devices and comprehensive patient care. The company generates revenue through the sale of its products, as well as through service agreements and long-term partnerships with healthcare providers. LivaNova invests heavily in research and development (R&D) to maintain its competitive edge and to bring innovative solutions to market.

The company also collaborates with hospitals, clinics, and research institutions to ensure its products meet the highest standards of efficacy and safety. By focusing on both product innovation and customer support, LivaNova has established itself as a trusted partner in the medical community.

Strategic Direction

LivaNova is committed to driving growth through innovation, sustainability, and global expansion. Key strategic priorities include:

  • Product Innovation: Developing next-generation devices for cardiovascular and neuromodulation therapies.
  • Geographic Expansion: Increasing its presence in emerging markets to tap into new patient populations.
  • Sustainability Goals: Reducing the environmental impact of its operations and products.
  • Digital Health Integration: Leveraging data analytics and digital platforms to enhance patient outcomes and streamline healthcare delivery.

Competitive Landscape

LivaNova operates in a highly competitive market, facing competition from both large multinational corporations and specialized medical device companies. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of cardiovascular and neuromodulation products.
  • Boston Scientific: Known for its innovative solutions in cardiology and neurology.
  • Abbott Laboratories: A major player in the cardiovascular space, particularly in heart valves and electrophysiology.
  • Edwards Lifesciences: Specializes in heart valve technologies and critical care monitoring.

Despite the competition, LivaNova differentiates itself through its focus on niche markets and its commitment to innovation.

Risk Factors

Like any global company, LivaNova faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Regulatory Challenges: Compliance with stringent medical device regulations in different countries.
  • Market Dependence: Heavy reliance on the success of its core products, particularly in the neuromodulation segment.
  • Supply Chain Disruptions: Potential delays or shortages in the supply of critical components.
  • Economic Uncertainty: Fluctuations in global economic conditions that could affect healthcare spending.

Recent Developments

LivaNova has made significant strides in recent years, including:

  • Launch of New Products: Introduction of advanced VNS devices and upgrades to its cardiovascular product line.
  • Strategic Acquisitions: Acquiring smaller companies to enhance its technological capabilities and market reach.
  • COVID-19 Response: Implementing measures to ensure the safety of its employees and the continuity of its operations during the pandemic.

Investment Considerations

For investors, LivaNova offers a mix of strengths and risks:

Strengths

  • Strong market position in cardiovascular and neuromodulation segments.
  • Robust pipeline of innovative products.
  • Global presence and diversified revenue streams.

Risks

  • Dependence on a few key products for revenue.
  • Exposure to regulatory and economic uncertainties.
  • Intense competition in the medical device industry.

Conclusion

LivaNova PLC is a leading player in the medical technology sector, with a strong focus on innovation and patient care. The company’s diversified portfolio, global reach, and commitment to sustainability position it well for future growth. However, investors should carefully consider the risks associated with regulatory challenges and market competition. Overall, LivaNova remains a compelling choice for those seeking exposure to the healthcare and medical device industries.